A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients

Leyh-Bannurah, Sami-Ramzi; Dell’Oglio, Paolo; Tian, Zhe; Schiffmann, Jonas; Shariat, Shahrokh F.; Suardi, Nazareno; Montorsi, Francesco; Briganti, Alberto; Heinzer, Hans; Huland, Hartwig; Graefen, Markus; Budäus, Lars; Karakiewicz, Pierre I.

doi:10.1007/s00345-016-1863-x

Cited by 18 publications

(10 citation statements)

References 25 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[93][94][95][96] The tables give the probability (95% CI) that a patient with a certain clinical stage, Gleason score, and PSA will have a cancer of each pathologic stage. Nomograms can be used to inform treatment decision-making for men contemplating active surveillance, [97][98][99] radical prostatectomy, 100-103 neurovascular bundle preservation, [104][105][106] or omission of pelvic lymph node dissection during radical prostatectomy, [107][108][109][110] brachytherapy, 100,111-113 or external beam RT (EBRT). 100,114 Biochemical progression-free survival (PFS) can be reassessed postoperatively using age, diagnostic serum PSA, and pathologic grade and stage.…”

Section: Nomogramsmentioning

confidence: 99%

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Mohler

Antonarakis

Armstrong

et al. 2019

Journal of the National Comprehensive Cancer Network

1,088

841

View full text Add to dashboard Cite

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.

show abstract

Section: Nomogramsmentioning

confidence: 99%

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Mohler

Antonarakis

Armstrong

et al. 2019

Journal of the National Comprehensive Cancer Network

1,088

841

View full text Add to dashboard Cite

show abstract

“…However, a prospective study including all predictors of upgrading and upstaging is ongoing, and results will be soon available. In terms of upstaging age, prostate volume and PSA levels are well established and already included in clinical nomograms for the prediction of upstaging …”

Section: Discussionmentioning

confidence: 99%

Urotensin II receptor expression in prostate cancer patients: A new possible marker

Giulianelli¹,

Nardoni²,

Falavolti³

et al. 2018

The Prostate

View full text Add to dashboard Cite

Background: Urotensin II receptor has been poorly studied in prostate cancer. To evaluate the expression of urotensin II receptor (UII-R) in patients undergoing radical prostatectomy.Methods: Overall, we identified 140 patients treated with retropubic radical prostatectomy (RP) in one center. UII-R was evaluated in prostate biopsies with immunohistochemical staining, resulting in a granular cytoplasmic positivity, through automated system using the kit Urotensin II Receptor Detection System provided by Pharmabullet srl. Immunostained slides were independently and blindly evaluated by ten uro-pathologists. To evaluate UTII-R expression three different parameters were considered: localization, granules dimensions and intensity of expression. A score from 0 to 3 was applied to each parameter to obtain a score from 0 to 9. Each parameter and the total score were evaluated as predictors of high grade disease on surgical pathology and of advanced stage disease. Accuracy of total score for the prediction of upgrading and upstaging was analyzed using receiver operator characteristics curve and decision curve analysis (DCA).Results: On radical prostatectomy 92/140 (66%) presented high grade disease on surgical pathology. Patients with high grade disease presented an apical distribution of the receptor, larger granules and a more intense expression when compared to patients with low grade disease. A well they presented a higher total score. Subscores and total scores were found to be predictors of upgrading and upstaging. On ROC analysis total score presented an AUC of 0.72 and 0.70, respectively, for the prediction of upgrading and upstaging. On DCA total score showed a clinical benefit in the prediction of adverse pathological outcomes.Conclusion: Urotensin II receptor is a potential marker of adverse pathological outcomes. Further studies should confirm our data and evaluate its role as a prognostic marker. K E Y W O R D S accuracy, upgrading, upstaging, urotensin 288 |

show abstract

“…In the past years, thousands of predictive models have been developed to predict outcomes after surgery. In urology, several predictive models have been developed both in oncological and stones field; however, only one model demonstrates to predict stone free status after ULT [10,12,[24][25][26][27][28][29][30][31]. The Japanese group of Imamura was the first to publish a nomogram to predict ULT efficacy [12].…”

Section: Discussionmentioning

confidence: 99%

Development of a nomogram predicting the probability of stone free rate in patients with ureteral stones eligible for semi-rigid primary laser uretero-litothripsy

et al. 2021

View full text Add to dashboard Cite

Purpose Few tools are available to predict uretero-lithotripsy outcomes in patients with ureteral stones. Aim of our study was to develop a nomogram predicting the probability of stone free rate in patients undergoing semi-rigid uretero-lithotripsy (ULT) for ureteral stones. Methods From January 2014 onwards, patients undergoing semi-rigid Ho: YAG laser uretero-lithotripsy for ureteral stones were prospectively enrolled in two centers. Patients were preoperatively evaluated with accurate clinical history, urinalysis and renal function. Non-contrast CT was used to define number, location and length of the stones and eventually the presence of hydronephrosis. A nomogram was generated based on the logistic regression model used to predict ULT success. Results Overall, 356 patients with mean age of 54 years (IQR 44/65) were enrolled. 285/356 (80%) patients were stone free at 1 month. On multivariate analysis single stone (OR 1.93, 95% CI 1.05–3.53, p = 0.034), stone size (OR 0.92, 95% CI 0.87–0.97, p = 0.005), distal position (OR 2.12, 95% CI 1.29–3.48, p = 0.003) and the absence of hydronephrosis (OR 2.02, 95% CI 1.08–3.78, p = 0.029) were predictors of success and these were used to develop a nomogram. The nomogram based on the model presented good discrimination (area under the curve [AUC]: 0.75), good calibration (Hosmer–Lemeshow test, p > 0.5) and a net benefit in the range of probabilities between 15 and 65%. Internal validation resulted in an AUC of 0.74. Conclusions The implementation of our nomogram could better council patients before treatment and could be used to identify patients at risk of failure. External validation is warranted before its clinical implementation.

show abstract

A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients

Cited by 18 publications

References 25 publications

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Urotensin II receptor expression in prostate cancer patients: A new possible marker

Development of a nomogram predicting the probability of stone free rate in patients with ureteral stones eligible for semi-rigid primary laser uretero-litothripsy

Contact Info

Product

Resources

About